Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Alnylam Pharmaceuticals Inc (NASDAQ:ALNY)

79.97
Delayed Data
As of Jun 28
 +0.14 / +0.18%
Today’s Change
31.38
Today|||52-Week Range
86.92
+113.60%
Year-to-Date
7 Outperforming Stocks With Rising Prices
Jun 27 / GuruFocus News - Paid Partner Content
Why is Alnylam's (ALNY) Stock Close to 100% this Year?
Jun 15 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close79.83
Today’s open80.50
Day’s range78.69 - 80.88
Volume1,082,066
Average volume (3 months)1,063,407
Market cap$7.3B
Dividend yield--
Data as of 3:59pm ET, 06/28/2017

Growth & Valuation

Earnings growth (last year)-38.84%
Earnings growth (this year)-9.48%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+14.75%
P/E ratioNM
Price/Sales67.96
Price/Book7.46

Competitors

 Today’s
change
Today’s
% change
SGENSeattle Genetics Inc+3.33+6.48%
TSROTESARO Inc+3.19+2.26%
RDYDr.Reddy's Laborator...+0.22+0.53%
IONSIonis Pharmaceutical...+1.44+2.74%
Data as of 4:02pm ET, 06/28/2017

Financials

Next reporting dateAugust 10, 2017
EPS forecast (this quarter)-$1.23
Annual revenue (last year)$47.2M
Annual profit (last year)-$410.1M
Net profit margin-869.63%

Profile

Sector
Health Technology
Industry
Biotechnology
Chief Executive Officer &
Director
John M. Maraganore
President
Barry E. Greene
Corporate headquarters
Cambridge, Massachusetts

Forecasts